Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC201 after radiotherapy for newly diagnosed H3 K27M-mutant diffuse glioma
jRCT2051240141Recruiting
- Sponsor
- Chimerix Inc.
- Start
- Oct 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of dordaviprone in diffuse midline glioma (DMG) (3 arms), sponsored by Chimerix Inc. Primary endpoints: Overall survival and Progression-free survival by RANO-HGG criteria. Started Oct 2024; status: recruiting.
02
Drugs
dordaviprone
03
Conditions
diffuse midline glioma (DMG)
Beyond the preview
Go deeper on jRCT2051240141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240141.